| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/21/2023 | 4.38% | Barclays | $16 → $15 | Maintains | Equal-Weight |
| 08/18/2023 | 53.1% | UBS | $23 → $22 | Maintains | Buy |
| 08/18/2023 | 143.56% | Benchmark | → $35 | Reiterates | Buy → Buy |
| 08/18/2023 | 735.07% | Baird | $140 → $120 | Maintains | Neutral |
| 07/27/2023 | -9.53% | JP Morgan | → $13 | Downgrades | Overweight → Equal-Weight |
| 07/25/2023 | 11.34% | HSBC | $17 → $16 | Maintains | Hold |
| 06/08/2023 | 60.06% | UBS | $35 → $23 | Maintains | Buy |
| 06/05/2023 | 143.56% | Benchmark | → $35 | Reiterates | Buy → Buy |
| 06/02/2023 | 143.56% | Benchmark | → $35 | Reiterates | Buy → Buy |
| 06/02/2023 | 73.97% | B of A Securities | $28 → $25 | Maintains | Buy |
| 06/02/2023 | 67.01% | Citigroup | $28 → $24 | Maintains | Buy |
| 06/02/2023 | 18.3% | HSBC | $22 → $17 | Maintains | Hold |
| 03/03/2023 | 143.56% | Benchmark | → $35 | Reiterates | → Buy |
| 03/03/2023 | 94.85% | Citigroup | → $28 | Upgrades | Neutral → Buy |
| 01/09/2023 | 76.06% | Goldman Sachs | $22.2 → $25.3 | Maintains | Neutral |
| 11/30/2022 | 54.49% | Goldman Sachs | $25.6 → $22.2 | Maintains | Neutral |
| 11/30/2022 | 11.34% | Barclays | $13 → $16 | Maintains | Equal-Weight |
| 11/03/2022 | -19.97% | B of A Securities | $42 → $11.5 | Downgrades | Buy → Neutral |
| 10/28/2022 | -9.53% | Barclays | $21 → $13 | Maintains | Equal-Weight |
| 10/27/2022 | -16.49% | Citigroup | $38 → $12 | Downgrades | Buy → Neutral |
| 10/25/2022 | 39.18% | JP Morgan | $30 → $20 | Maintains | Overweight |
| 09/09/2022 | 108.77% | Benchmark | $56 → $30 | Maintains | Buy |
| 09/09/2022 | 108.77% | UBS | $40 → $30 | Maintains | Buy |
| 09/09/2022 | 46.14% | Barclays | $26 → $21 | Maintains | Equal-Weight |
| 09/07/2022 | — | JP Morgan | Assumes | → Overweight | |
| 06/13/2022 | 73.97% | JP Morgan | $19 → $25 | Maintains | Neutral |
| 06/10/2022 | 213.15% | Citigroup | $46 → $45 | Maintains | Buy |
| 06/10/2022 | 80.93% | Barclays | $24 → $26 | Maintains | Equal-Weight |
| 05/25/2022 | 76.06% | CLSA | $33.4 → $25.3 | Maintains | Outperform |
| 05/16/2022 | 32.22% | JP Morgan | $15 → $19 | Upgrades | Underweight → Neutral |
| 05/03/2022 | 67.01% | Barclays | $32 → $24 | Maintains | Equal-Weight |
| 03/14/2022 | 4.38% | JP Morgan | → $15 | Downgrades | Overweight → Underweight |
| 03/04/2022 | 421.92% | Benchmark | $86 → $75 | Maintains | Buy |
| 02/18/2022 | 199.23% | Goldman Sachs | $105 → $43 | Downgrades | Buy → Neutral |
| 02/08/2022 | 122.69% | Barclays | → $32 | Initiates Coverage On | → Equal-Weight |
| 01/11/2022 | 213.15% | Bernstein | → $45 | Downgrades | Outperform → Market Perform |
| 12/28/2021 | 498.47% | Benchmark | → $86 | Initiates Coverage On | → Buy |
| 08/20/2021 | 783.79% | HSBC | $140 → $127 | Maintains | Buy |
| 08/13/2021 | 665.48% | Deutsche Bank | → $110 | Initiates Coverage On | → Buy |
| 07/26/2021 | 693.32% | CLSA | $128 → $114 | Downgrades | Buy → Outperform |
| 07/23/2021 | 874.25% | HSBC | $136 → $140 | Maintains | Buy |
| 05/14/2021 | 595.89% | 86 Research | $103 → $100 | Upgrades | Hold → Buy |
| 04/08/2021 | 874.25% | Credit Suisse | → $140 | Upgrades | Neutral → Outperform |
| 02/09/2021 | 909.05% | Credit Suisse | $110 → $145 | Downgrades | Outperform → Neutral |
| 01/25/2021 | 1013.43% | Bernstein | → $160 | Initiates Coverage On | → Outperform |
| 08/27/2020 | — | Nomura | Downgrades | Buy → Neutral | |
| 07/17/2020 | — | BOCOM International | Downgrades | Buy → Neutral | |
| 05/27/2020 | 178.36% | Morgan Stanley | → $40 | Upgrades | Equal-Weight → Overweight |
| 05/21/2020 | 192.28% | JP Morgan | → $42 | Upgrades | Neutral → Overweight |
| 05/20/2020 | 171.4% | Nomura | $36 → $39 | Maintains | Buy |
| 05/18/2020 | 150.52% | Nomura | $28 → $36 | Maintains | Buy |
| 03/19/2020 | 101.81% | UBS | $31 → $29 | Maintains | Buy |
| 01/10/2020 | 67.01% | Morgan Stanley | → $24 | Downgrades | Overweight → Equal-Weight |
| 11/20/2019 | 39.18% | Nomura | $18 → $20 | Maintains | Buy |
| 10/09/2019 | 25.26% | Nomura | → $18 | Initiates Coverage On | → Buy |
| 08/27/2019 | 39.18% | Citigroup | $23 → $20 | Maintains | Buy |
| 08/07/2019 | 49.62% | Goldman Sachs | → $21.5 | Initiates Coverage On | → Buy |
| 08/05/2019 | 24.57% | Jefferies | → $17.9 | Initiates Coverage On | → Buy |
| 03/01/2019 | 39.18% | JP Morgan | $17 → $20 | Downgrades | Overweight → Neutral |
| 02/27/2019 | — | China Renaissance | Initiates Coverage On | → Buy | |
| 01/31/2019 | 53.1% | Citigroup | → $22 | Initiates Coverage On | → Buy |
| 01/14/2019 | — | Daiwa Capital | Initiates Coverage On | → Outperform | |
| 09/24/2018 | -23.45% | Morgan Stanley | $13.5 → $11 | Downgrades | Overweight → Equal-Weight |
| 09/11/2018 | 4.38% | B of A Securities | $17.3 → $15 | Maintains | Buy |
| 08/29/2018 | -2.57% | JP Morgan | $16 → $14 | Maintains | Overweight |
What is the target price for Bilibili (BILI)?
The latest price target for Bilibili (NASDAQ: BILI) was reported by Barclays on August 21, 2023. The analyst firm set a price target for $15.00 expecting BILI to rise to within 12 months (a possible 4.38% upside). 25 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Bilibili (BILI)?
The latest analyst rating for Bilibili (NASDAQ: BILI) was provided by Barclays, and Bilibili maintained their equal-weight rating.
When is the next analyst rating going to be posted or updated for Bilibili (BILI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bilibili, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bilibili was filed on August 21, 2023 so you should expect the next rating to be made available sometime around August 21, 2024.
Is the Analyst Rating Bilibili (BILI) correct?
While ratings are subjective and will change, the latest Bilibili (BILI) rating was a maintained with a price target of $16.00 to $15.00. The current price Bilibili (BILI) is trading at is $14.37, which is out of the analyst's predicted range.